RU2010117178A - Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний - Google Patents

Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний Download PDF

Info

Publication number
RU2010117178A
RU2010117178A RU2010117178/15A RU2010117178A RU2010117178A RU 2010117178 A RU2010117178 A RU 2010117178A RU 2010117178/15 A RU2010117178/15 A RU 2010117178/15A RU 2010117178 A RU2010117178 A RU 2010117178A RU 2010117178 A RU2010117178 A RU 2010117178A
Authority
RU
Russia
Prior art keywords
eye
scaav
interfering rna
vector
rna molecule
Prior art date
Application number
RU2010117178/15A
Other languages
English (en)
Russian (ru)
Inventor
Аллан Р. ШЕПАРД (US)
Аллан Р. ШЕПАРД
Original Assignee
Алькон Рисерч, Лтд. (Us)
Алькон Рисерч, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алькон Рисерч, Лтд. (Us), Алькон Рисерч, Лтд. filed Critical Алькон Рисерч, Лтд. (Us)
Publication of RU2010117178A publication Critical patent/RU2010117178A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2010117178/15A 2007-10-01 2008-10-01 Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний RU2010117178A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97655207P 2007-10-01 2007-10-01
US60/976,552 2007-10-01

Publications (1)

Publication Number Publication Date
RU2010117178A true RU2010117178A (ru) 2011-11-10

Family

ID=40042637

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010117178/15A RU2010117178A (ru) 2007-10-01 2008-10-01 Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний

Country Status (12)

Country Link
US (1) US20090087413A1 (https=)
EP (1) EP2192926A1 (https=)
JP (1) JP2010540564A (https=)
KR (1) KR20100061792A (https=)
CN (1) CN101815536A (https=)
AU (1) AU2008308784B2 (https=)
BR (1) BRPI0817937A2 (https=)
CA (1) CA2694091A1 (https=)
MX (1) MX2010001608A (https=)
RU (1) RU2010117178A (https=)
WO (1) WO2009046059A1 (https=)
ZA (1) ZA201000423B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2287323A1 (en) 2009-07-31 2011-02-23 Association Institut de Myologie Widespread gene delivery to the retina using systemic administration of AAV vectors
HRP20190144T1 (hr) * 2010-04-23 2019-03-22 University Of Florida Research Foundation, Inc. Pripravci raav-gvanilat ciklaze i postupci za liječenje leberove urođene amauroze-1 (lca1)
CN103505743A (zh) 2012-06-21 2014-01-15 北京命码生科科技有限公司 含功能性microRNA/siRNA的细胞微粒子及其应用
EP4012035B1 (en) * 2014-09-16 2024-11-06 Genzyme Corporation Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
PT4012035T (pt) * 2014-09-16 2025-02-11 Genzyme Corp Vetores virais adenoassociados para tratar o glaucoma de miocilina (mioc)
BR112017005235B1 (pt) * 2014-09-16 2023-10-31 Genzyme Corporation Vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
GB201809588D0 (en) * 2018-06-12 2018-07-25 Univ Bristol Materials and methods for modulating intraocular and intracranial pressure
AU2020361533A1 (en) 2019-10-08 2022-04-28 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
IL296103A (en) 2020-03-05 2022-11-01 Neotx Therapeutics Ltd Methods and compositions for treating cancer with immune cells
WO2021245224A1 (en) * 2020-06-05 2021-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating ocular diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522840A (en) * 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
US20040209832A1 (en) * 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050048529A1 (en) * 2002-02-20 2005-03-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20060229266A1 (en) * 2003-08-13 2006-10-12 Kumar Nalin M Silencing of tgf-beta receptor type II expression by sirna
WO2006042252A2 (en) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白A的RNAi抑制作用
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
TW200639252A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
KR20080018858A (ko) * 2005-03-11 2008-02-28 알콘, 인코퍼레이티드 녹내장 치료용 플리즐 관련 단백질―1의 RNAⅰ-중재저해
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
AR057252A1 (es) * 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
TW200731980A (en) * 2005-12-29 2007-09-01 Alcon Mfg Ltd RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
US8298818B2 (en) * 2006-04-28 2012-10-30 University Of Florida Research Foundation, Inc. Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
ES2413804T3 (es) * 2006-05-19 2013-07-17 Alcon Research, Ltd. Inhibición mediada por ARNi de estados relacionados con factor de necrosis tumoral-alfa
CN102743767A (zh) * 2006-08-24 2012-10-24 爱尔康研究有限公司 RNAi介导的Gremlin抑制用于治疗眼内压相关的状况
US7872119B2 (en) * 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
US7973019B1 (en) * 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
TW200932274A (en) * 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof

Also Published As

Publication number Publication date
MX2010001608A (es) 2010-03-15
US20090087413A1 (en) 2009-04-02
BRPI0817937A2 (pt) 2015-04-07
CA2694091A1 (en) 2009-04-09
CN101815536A (zh) 2010-08-25
JP2010540564A (ja) 2010-12-24
KR20100061792A (ko) 2010-06-09
ZA201000423B (en) 2011-03-30
WO2009046059A1 (en) 2009-04-09
AU2008308784A1 (en) 2009-04-09
AU2008308784B2 (en) 2013-07-18
EP2192926A1 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
RU2010117178A (ru) Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний
Casson Medical therapy for glaucoma: A review
JP2010540564A5 (https=)
Guzman‐Aranguez et al. Small‐interfering RNA s (siRNA s) as a promising tool for ocular therapy
NZ725574A (en) Compounds for treating ophthalmic diseases and disorders
JP2021512904A5 (https=)
JP2010501188A5 (https=)
JP2021522180A5 (https=)
US20240124538A1 (en) Modulation of Wnt5a to Treat Glaucoma
CN102164600A (zh) 用于治疗眼的新血管发生病症的包含索拉菲尼的眼科药物组合物
Li et al. A new approach of delivering siRNA to the cornea and its application for inhibiting herpes simplex keratitis
Yang et al. Inhibitory effects of polysaccharide extract from Spirulina platensis on corneal neovascularization
WO2015187840A2 (en) Methods and formulations for treatment of ocular disorders
Hnik et al. Antisense oligonucleotide therapy in diabetic retinopathy
ATE491715T1 (de) Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
Roddy et al. Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility
RU2008120702A (ru) Модулирование экспрессии 11бета-гидроксистероидной дегидрогеназы 1 для лечения глазных болезней
Yuan et al. Lentivirus-mediated RNA interference of vascular endothelial growth factor in monkey eyes with iris neovascularization
RU2015112131A (ru) КиРНК И ИХ ИСПОЛЬЗОВАНИЕ В СПОСОБАХ И КОМПОЗИЦИЯХ ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРОФИЛАКТИКИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ
ES2624446T3 (es) Compuestos donantes de óxido nítrico a base de quinona para uso oftalmológico
WO2013070821A1 (en) Methods and compositions for treating diseases, disorders or injury of the nervous system
Lu et al. A novel and effective human hepatocyte growth factor kringle 1 domain inhibits ocular neovascularization
Wang et al. Intravitreal injection of triamcinolone acetonide for macular edema due to retinitis pigmentosa and other retinal diseases
RU2343885C1 (ru) Способ лечения субэпителиального флера роговицы после фоторефракционной кератэктомии
JPWO2020180865A5 (https=)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130621